menu

Optimizing the Care and Quality of Life for Patients with ADPKD – Part 2: Progression and Prognostication

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Optimizing the Care and Quality of Life for Patients with ADPKD – Part 2: Progression and Prognostication

close
0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    This Expert Exchange webcast aims to improve clinicians’ ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.

  • Target Audience

    This activity has been designed to meet the educational needs of primary care and family physicians, nephrologists and other healthcare professionals who manage patients with polycystic kidney disease.

  • Learning Objectives

    Upon completion of this activity, participants will be better able to do the following:

    • Recognize tools and resources including Mayo Classification system and imaging to monitor disease progression.
    • Describe relationships between total kidney volume, measured GFR and age for detecting rapid progressors.
    • Apply the PROPKD scoring system to predict renal survival in ADPKD.
  • Financial Support

    This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

  • Provider(s)/Educational Partner(s)

    Jointly provided by AXIS Medical Education and Novus Medical Education.

  • Accreditation and Credit Designation Statements

    ReachMD Healthcare ImageIn support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Novus Medical Education. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians:

    AXIS Medical Education designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified andmitigated prior to initiation of the planning phase for an activity

    AXIS has mitigated and disclosed to learners all relevant conflicts of interestdisclosed by staff, planners, faculty/authors, peer reviewers or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Faculty

    Dr. Dahl discloses the following relationships:
    Advisor/Consultant: Natera, Otsuka America Pharmaceutical
    Research Support: Reata Pharmaceuticals, Regulus Therapeutics,Sanofi,

    Dr. Lanktree discloses the following relationships:
    Advisor/Consultant: Bayer AG, Genzyme, Otsuka, Reata, Sanofi
    Speakers Bureau: Otsuka

    Planners and Managers
    The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:

    Steven Scrivner, MPA, CHCP – nothing to disclose
    Melanie Joy, PharmD, PhD – Equity Interest/Officer: Katharos, Inc.; Advisor/Consultant: Vifor Pharma
    Ronald Viggiani, MD – nothing to disclose
    Dee Morgillo, MEd., CHCP – nothing to disclose

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Method of Participation

    There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

    1. Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the pre-test.
    3. View the webcast.
    4. Complete the post-test and evaluation.
    5. Physicians who receive a grade of 75% or better on the post-test and complete the evaluation will receive a CME certificate.
    6. All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.
  • CME Provider

    For information about the certification of this activity, please contact AXIS at info@axismeded.com.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    This Expert Exchange webcast aims to improve clinicians’ ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.

  • Target Audience

    This activity has been designed to meet the educational needs of primary care and family physicians, nephrologists and other healthcare professionals who manage patients with polycystic kidney disease.

  • Learning Objectives

    Upon completion of this activity, participants will be better able to do the following:

    • Recognize tools and resources including Mayo Classification system and imaging to monitor disease progression.
    • Describe relationships between total kidney volume, measured GFR and age for detecting rapid progressors.
    • Apply the PROPKD scoring system to predict renal survival in ADPKD.
  • Financial Support

    This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

  • Provider(s)/Educational Partner(s)

    Jointly provided by AXIS Medical Education and Novus Medical Education.

  • Accreditation and Credit Designation Statements

    ReachMD Healthcare ImageIn support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Novus Medical Education. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians:

    AXIS Medical Education designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified andmitigated prior to initiation of the planning phase for an activity

    AXIS has mitigated and disclosed to learners all relevant conflicts of interestdisclosed by staff, planners, faculty/authors, peer reviewers or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Faculty

    Dr. Dahl discloses the following relationships:
    Advisor/Consultant: Natera, Otsuka America Pharmaceutical
    Research Support: Reata Pharmaceuticals, Regulus Therapeutics,Sanofi,

    Dr. Lanktree discloses the following relationships:
    Advisor/Consultant: Bayer AG, Genzyme, Otsuka, Reata, Sanofi
    Speakers Bureau: Otsuka

    Planners and Managers
    The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:

    Steven Scrivner, MPA, CHCP – nothing to disclose
    Melanie Joy, PharmD, PhD – Equity Interest/Officer: Katharos, Inc.; Advisor/Consultant: Vifor Pharma
    Ronald Viggiani, MD – nothing to disclose
    Dee Morgillo, MEd., CHCP – nothing to disclose

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Method of Participation

    There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

    1. Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the pre-test.
    3. View the webcast.
    4. Complete the post-test and evaluation.
    5. Physicians who receive a grade of 75% or better on the post-test and complete the evaluation will receive a CME certificate.
    6. All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.
  • CME Provider

    For information about the certification of this activity, please contact AXIS at info@axismeded.com.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule24 Oct 2021
Webpack App